WO2012009712A2 - Methods and compositions including spore-forming bacteria for increasing the health of animals - Google Patents

Methods and compositions including spore-forming bacteria for increasing the health of animals Download PDF

Info

Publication number
WO2012009712A2
WO2012009712A2 PCT/US2011/044326 US2011044326W WO2012009712A2 WO 2012009712 A2 WO2012009712 A2 WO 2012009712A2 US 2011044326 W US2011044326 W US 2011044326W WO 2012009712 A2 WO2012009712 A2 WO 2012009712A2
Authority
WO
WIPO (PCT)
Prior art keywords
deposit number
atcc deposit
poultry
animal
bacterial
Prior art date
Application number
PCT/US2011/044326
Other languages
French (fr)
Other versions
WO2012009712A3 (en
Inventor
Billy Hargis
Ross Wolfenden
Neil Pumford
Anita Menconi
Guillermo Tellez
Original Assignee
The Board Of Trustees Of The University Of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Arkansas filed Critical The Board Of Trustees Of The University Of Arkansas
Priority to US13/810,549 priority Critical patent/US9005601B2/en
Priority to BR112013001107-6A priority patent/BR112013001107B1/en
Priority to EP11807617.3A priority patent/EP2593187A4/en
Publication of WO2012009712A2 publication Critical patent/WO2012009712A2/en
Publication of WO2012009712A3 publication Critical patent/WO2012009712A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates in general to methods for improving the health of agricultural animals.
  • the present invention relates to bacterial isolates, probiotic formulations comprising the isolates and methods selecting and of using the probiotic formulations and isolates to improve the health of poultry.
  • the bacterial isolates are Bacillus spp. selected from environmental sources that are capable of improving the health of poultry. These isolates were selected for their ability to 1) reduce Salmonella or other food-bome bacteria pathogenic to humans, 2) improve production parameters in commercial poultry operations, or 3) reduce enteric poultry bacterial pathogens. No known Bacillus DFM product, Bacillus isolate, or combination of Bacillus isolates are able to accomplish al l three tasks.
  • methods for improving gastrointestinal tract health in animals include administering an endospore-forming bacterium to an animal.
  • the endospore-forming bacteria are capable of reducing the number or growth of bacterial pathogens in the gastrointestinal tract of the animal.
  • administration of the endospore-forming bacterium to the animal improves at least one production parameter in the animal.
  • bacterial isolates selected using the methods disclosed herein include Bacillus subtilis AM0904 (ATCC Deposit Number ###-###), Bacillus subtilis AM0911 (ATCC Deposit Number ###-###), Bacillus subtilis NP122 (ATCC Deposit Number ###-###), Bacillus subtilis ⁇ 9 ⁇ (ATCC Deposit Number ###-###), B. licheniformis B l (ATCC Deposit Number ###-###), B. subtilis B2 (ATCC Deposit Number ###-###), B. licheniformis W25 (ATCC Deposit Number ###-###), B. licheniformis RW32 (ATCC Deposit Number ###-###), and B. licheniformis RW41 (ATCC Deposit Number ###-###).
  • multi-isblate combinations and probiotic compositions of the bacterial isolates disclosed herein are provided.
  • a combination of B. subtilis (one or more distinct isolates or strains) and/or B. licheniformis (at least one isolate) is provided.
  • the bacterial isolates and probiotic formulations provided here improve upon current technology because they increase performance of commercial poultry, diminish common bacterial pathogens from within the gut of commercial poultry, and reduce common food-borne illness-associated bacteria, such as Salmonella, from within the gut of commercial poultry.
  • animal feed comprising the probiotic compositions or bacterial isolates disclosed herein is provided.
  • the feed may comprise between about 10 4 and 10 9 cfu/gm finished feed.
  • methods for improving poultry health include administration of the probiotic formulation or the animal feed described herein to an animal.
  • the gastrointestinal health of the animal may be improved by the method.
  • methods of selecting bacterial strains for use in probiotic formulations include selecting facultative anaerobic bacterial strains capable of forming endospores, selecting bacterial strains capable of reducing growth of pathogenic bacteria such as Salmonella enteritidis, Salmonella iyphinmrium, Campylobacter jejuni or Clostridium perfringens in mixed cultures in vitro or in the gastrointestinal tract of animals, selecting bacterial strains capable of improving the growth rate of commercial poultry, reducing the severity of necrotic enteritis and/or persisting in the gastrointestinal tract of poultry and removing any selected bacterial strains not considered GRAS (Generally Regarded As Safe) by the Food and Drug Administration (FDA), not eligible for inclusion into animal feed by the Association of American Feed Control Officials (AAFCO) or capable of hemolysis of sheep red blood cells.
  • pathogenic bacteria such as Salmonella enteritidis, Salmonella iyphinmrium, Campylobacter jejuni or Clostridium perfringens in mixed cultures in vitro or
  • Figure 1 is a diagram of the in vitro portion of the isolate selection procedures used to isolate and select candidate probiotic DFM isolates.
  • Figure 2 is a diagram of the in vivo portion of the isolate selection procedures used to isolate and select candidate probiotic DFM isolates.
  • compositions and bacterial isolates for improved gastrointestinal health of poultry are disclosed.
  • the compositions include probiotic formulations or Direct-Fed Microbials (DFM) and animal feed products.
  • Methods of administration to improve animal health and reduce contamination of the human food chain and methods for isolating specific bacterial strains useful in the methods are also disclosed.
  • the methods and compositions provided herein also produce greater consistency of production parameters within a group of animals.
  • Methods for improving gastrointestinal tract health in animals include administering an endospore-forming bacterium to an animal.
  • the bacteria may be administered as spores, but need not be.
  • the endospore-forming bacteria are capable of reducing the ability of bacterial pathogens to grow in the gastrointestinal tract of the animal.
  • the number of bacterial pathogens found within the gastrointestinal tract is reduced in animals administered the endospore-forming bacteria as compared to control animals not administered the bacteria.
  • Bacterial pathogens refers to bacteria capable of causing disease i.e., morbidity or mortality, in either the animal being administered the bacteria or humans.
  • Pathogenic bacteria also include those bacteria capable of causing food-borne illness in humans.
  • the endospore-forming bacteria can be any bacteria capable of sporulation such as those of the genus Bacillus, in particular Bacillus subtilis or Bacillus licheniformis.
  • the endospore-forming bacteria are suitably not pathogenic, i.e., they are not capable of causing morbidity or mortality in the animals being treated.
  • the bacteria are facultative anaerobes and capable of replicating and/or persisting within the gastrointestinal tract of the animal.
  • the bacteria are Generally Regarded as Safe (GRAS) by the U.S. Food and Drug Administration (FDA) and acceptable for inclusion in an animal diet or water by the Association of American Feed Control Officials (AAFCO).
  • GRAS Generally Regarded as Safe
  • FDA U.S. Food and Drug Administration
  • AAFCO Association of American Feed Control Officials
  • the endospore-forming bacteria are not capable of causing hemolysis when incubated with or grown on media containing red blood cells.
  • the endospore-forming bacteria are
  • the gastrointestinal health includes the prevention of disease of the, gastrointestinal tract itself, such as necrotic enteritis of the intestines, or the pathogenic bacterial load of the intestines, ceca or lower intestine, and increase in production parameters for the treated animals as compared to controls.
  • Production parameters include but arc not limited to average daily weight gain, feed conversion rates, consistency of growth among a group of animals, ability to reproduce and bear healthy offspring, ability to produce eggs or milk and the quantity and quality of such production.
  • an exemplary composition or formulation can include one or more bacteria capable of forming endospores.
  • Bacteria capable of forming endospores include bacteria of the genus Bacillus. Specific B. subtilis and B. Hcheniformis bacterial isolates are disclosed herein, but other endospore forming bacteria suitable for use in the methods and compositions disclosed herein can be isolated and selected by those of skill in the art using the methods of selection described below and in the Examples.
  • a composition can comprise a formulation containing one or two different isolates of B. subtilis and/or one or two isolates of B. lichen iformis, wherein each isolate is independently selected to perform a specific role and/or function.
  • the combination of these isolates can be combined with an agricultural animal feed (specifically poultry feed) and ultimately used to improve the health and productivity of the agricultural animals (e.g. livestock and/or poultry).
  • an agricultural animal feed specifically poultry feed
  • the isolates and/or the combined isolate formulations can reduce pathogenic bacteria, in particular food- borne illness associated bacteria, that cause the eggs or meat to be contaminated, can reduce gut pathogens in the poultry, and increase weight gain or egg production of commercial poultry.
  • the isolates can decrease the occurrence or load of at least one of Salmonella, Campylobacter and Clostridium.
  • Salmonella Campylobacter
  • Clostridium a reduced level of Salmonella within the
  • gastrointestinal tract may lead to less carcass contamination as well as reduce the likelihood of Salmonella contaminated eggs.
  • the bacterial isolates were selected for their ability to form spores and as such are resistant to temperature extremes.
  • the selected bacteria are facultative anaerobes and are not hemolytic.
  • the bacteria are capable of inhibiting or reducing the growth of both gram positive and gram negative bacteria such as Salmonella, Clostridium and Campylobacter.
  • the ability to reduce pathogenic bacterial growth allows the selected bacteria to reduce necrotic enteritis in poultry.
  • the selected bacteria are also capable of increasing the growth rate and gastrointestinal health of commercial poultry and are capable of persisting and colonizing in the gastrointestinal tract of poultry.
  • the isolates are all considered as GRAS (Generally recognized as safe) by the FDA and are eligible for inclusion in animal feed by the AAFCO. Furthermore, these particular isolates are able to go through their entire life cycle within the gastrointestinal tract of agricultural animals, specifically in commercial poultry.
  • Bacillus subtilis AM0904 ATCC Deposit Number
  • Bacillus subtilis AM091 1 ATCC Deposit Number
  • Bacillus subtilis NP 122 ATCC Deposit Number
  • Bacillus subtilis NR1 19B ATCC Deposit Number
  • licheniformis B l ATCC Deposit Number
  • B. subtilis B2 ATCC Deposit Number
  • B. licheniformis RW25 ATCC Deposit Number
  • B. licheniformis RW32 ATCC Deposit Number
  • B. licheniformis RW41 ATCC Deposit Number
  • the spore, or inert, survival form of Bacillus spp. do not produce any known effectors which may reduce bacterial pathogens in the gastrointestinal tract or have other beneficial effects on the animal.
  • the vegetative form of the bacteria can produce effectors.
  • reactivation and germination of the spores after administration is likely important to the improvement of poultry gastrointestinal health.
  • the ability of Bacillus probiotic products to germinate within the gut of commercial poultry has not been adequately investigated.
  • the bacterial isolates described herein were also selected for their ability to reactivate ⁇ germinate and colonize or persist within animals after administration of spores of the bacteria to animals.
  • Probiotic formulations comprising at least one of the bacterial isolates provided herein are also disclosed.
  • the probiotic formulation may comprise a combination of the bacterial isolates disclosed herein or may include bacterial isolates other than those disclosed herein.
  • the bacteria used are capable of forming endospores, are capable of reducing the pathogenic bacterial loads in the gastrointestinal tract and are capable of increasing at least one production parameter.
  • the probiotic formulation may include at least one Bacillus sublilis strain and/or at least one Bacillus lichemformis strain.
  • the probiotic formulation may include two or more Bacillus sublilis strains or two or more Bacillus lichemformis strains.
  • the bacterial isolates may be used in any combination in the probiotic formulations.
  • a combination of NP122 and B2 may be used.
  • ⁇ ⁇ 22 and B2 may be used in combination with AM0904 or AM091 1. Any other possible combination of the bacterial isolates provided herein may also be made.
  • the ratio of one isolate to another in a combination probiotic formulation can vary within a wide range.
  • the ratio of bacterial isolates is between 0.1 : 1 and 10: 1 , suitably between 0.5: 1 and 5: 1 , more suitably 1 : 1 to 3: 1 , more suitably it is between 1 : 1 and 2: 1.
  • the ratio of NP 122 to B2 to AM0904 was 5:5: 1.
  • the ratios are based on the colony forming units (cfu) of the bacterial spores after reactivation. ,
  • the probiotic formulation is capable of improving the health of animals after administration to animals.
  • the probiotic formulation or animal feed comprising the probiotic formulation is capable of improving the gastrointestinal health of poultry. This may include reducing the incidence or severity of necrotic enteritis (by at least 10%, 15% or even 20% as compared to controls and mortality may be prevented), reducing the bacterial load in the intestines of the animal, specifically with regards to levels of at least one of Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry (at least 50% decrease in recovery, suitably at least 60%, 70%, 80%, 90% or even more of a decrease in recovery as compared to controls), and increasing the daily average weight gain of an animal (at least a 3% increase suitably at least a 5%, 7%, 10%, 20%, 30% 40%, 50%, 55%, 60% or even more increase in weight gain as compared to controls (measured as average daily weight gain)).
  • the feed conversion rate may also be increased as compared to controls. For example the feed conversion rate may
  • Administration of the probiotic formulation may also reduce the level or number of potential bacterial food-borne pathogens of humans in the gastrointestinal tract of commercial poultry.
  • the level of Salmonella and Campylobacter spp. in the gastrointestinal tract of animals administered the probiotic formulation may be reduced as compared to control animals not administered the probiotic or the spore-forming bacteria.
  • Such a reduction in potential human pathogen load in the gastrointestinal tract of poultry will limit the opportunity of contaminating the human food chain either during preparation of meat for human consumption or via contamination of poultry eggs or milk.
  • These isolates, probiotic formulations comprising the isolates or animal feed comprising the isolates or combinations thereof may be administered to animals orally.
  • Oral administration includes, but is not limited to, delivery in feed, water, by oral gavage or aerosol spray.
  • the animal is a poultry, more suitably a chicken or turkey. If supplied in an animal feed, the feed may comprise between 10 4 and 10 9 cfu bacteria/gm of finished feed.
  • the feed comprises between 10 5 and 5 x 10 7 cfu bacteria/gm feed.
  • the probiotic formulation may be added to the feed during production, after production by the supplier or by the person feeding the animals, just prior to providing the food to the animals.
  • the endospore-forming bacteria used in the methods and compositions described herein are particularly suitable because they are capable of surviving (as spores) the heat and pressure conditions of the process of producing a dry pelleted feed product.
  • isolates or isolate combinations for inclusion in the methods and including those isolates selected and described in the Examples are selected for inclusion in agricultural animal diets to increase overall gastrointestinal health, improve production performance, and reduce enteric bacterial pathogens of importance to both animal health and human food safety.
  • These isolates alone or in combination may be added to poultry diets at the rate of about 10 4 to 10 9 (l . lx l0 7 in the Examples) spores per gram of finished feed for optimal inclusion rate, if the bacteria or probiotic compositions being administered continuously. A higher inclusion rate may be necessary if spores of the bacteria or the compositions are provided intermittently.
  • the spores of these isolates may also be administered via the drinking water, through course spray, through aerosol spray, or through any other means by which the agricultural animals may ingest these isolates or combination of isolates.
  • Methods of isolating bacteria strains for inclusion in probiotic formulations are also provided herein and are depicted in Figures 1 and 2. The methods include both in vitro and in vivo tests to select bacteria from a source and may be completed in any order.
  • Sources of potential bacterial isolates include animal feces, environmental or soil samples, laboratory stocks of bacteria from tissue and cell supply warehouses such as the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • the bacteria may then be isolated and selected by selecting facultative anaerobic bacterial strains capable of forming spores; capable of reducing the growth of or killing Salmonella enteritidis, Salmonella typhimurium, Campylobacter jejuni and/or Clostridium perfringens; capable of improving growth rate of commercial poultry; capable of reducing the severity of necrotic enteritis; capable of persisting in the gastrointestinal tract of poultry.
  • the methods also include removing bacterial strains not considered GRAS by the FDA, not cligblc for inclusion into animal feed by AAFCO or those capable of hemolysis.
  • Bacterial strains fitting these criteria may then be included in probiotic formulations.
  • the present invention sets forth exemplary isolates, compositions, and methods for improving GI tract health in animals. It will be understood that the description is of exemplary embodiments of the invention, and that the invention is not limited to the specific forms shown. Various modifications may be made in the design and
  • TSA plates containing sheep blood were inoculated with the isolates and incubated for 24 h at 37°C. The plates were then evaluated and scored for level of hemolysis. All isolates causing alpha or beta hemolysis were not evaluated further. Similarly, further testing of any isolate whose colony morphology was consistent with that of the B. cere s group (B. cereus, B. mycoides, B. thurigensis, and B. anthrasis) was discontinued. Those isolates with the greatest in vitro antimicrobial activity (anti-SE) were identified using the bioMerieux API 50 CHB test kit.
  • Bacillus isolates identified using the above methods were further screened for in vitro microbial inhibitory activity "for Clostridium perfringen (CP) and Campylobacter jejuni.
  • a similar overlay method as described above was used, but overlays were incubated anaerobically and NO was not added to the overlay media.
  • Isolates which passed the in vitro testing were evaluated using a series of in vivo tests illustrated in Figure 2. These isolates were selected for further analysis in in vivo trials with poults and chicks due to their performance in the // vitro tests.
  • An antibiotic- free corn-soy turkey starter diet produced by the University of Arkansas Department of Poultry Science feed mill (Fayetteville, AR 72701 ) and formulated to meet or exceed the National Research Council requirements for critical nutrients of young poults and chicks was used as the basal diet for these experiments.
  • Spores from the candidate isolates were added to the basal diet at a concentration of about 10 6 cfu/gm of feed and mixed with a rotary mixer for 15 minutes to distribute spores throughout feed.
  • the cecal tonsils were aseptically removed and placed into tetrathionate broth.
  • the ceca were homogenized and diluted 1 :4 by weight with sterile saline.
  • Total viable counts of ST were determined by plating dilutions on BGA plates with NO (25 ⁇ g mL) and nalidixic acid (NA; 2( g mL) after 24 h of incubation at 37°C. The plates were examined for the presence of colonies typical of this strain of ST on BGA media. Isolates which produced body weight gains greater than control and led to a decreased recovery of ST were selected for further testing, while unsuccessful isolates were discarded.
  • Bacillus snbtilis strains AM0904 ATCC Deposit Number ###-###
  • AM091 1 ATCC Deposit Number ###-###
  • NP 122 ATCC Deposit Number ###-###
  • NPl 19B ATCC Deposit Number ###-###
  • the isolates were retested not as individual isolates, but in combinations of 2 to 3 isolates. These combinations were subjected to the
  • Combinations of the above listed isolates may include, but are not limited to, the following: NP l 22, AM0904, and B2. This combination has been shown to be effective when administered in the ratio of 5:5: 1 for isolates NP122, B2 and AM0904 respectively. When administered in the feed this combination has been show to be effective to yield significant (p ⁇ 0.05) reduction of Salmonella infection (50-90% decrease in recovery), necrotic enteritis mortality and lesions (22% in controls to 0% in treated), and improving body weight gain during challenge periods by more than 50% when administered at the rate of 5x l0 6 : 5xl 0 6 : lx lO 6 : spores per gram of finished feed for isolates NPl 22, B2 and AM0904, respectively.

Abstract

Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as Salmonella, Clostridium, and Campylobacter, in the gastrointestinal tract of the animal. The bacteria are also selected for the ability to improve at least one production parameter in the animal.

Description

METHODS AND COMPOSITIONS INCLUDING SPORE-FORMING BACTERIA FOR INCREASING THE HEALTH OF ANIMALS
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application claims the benefit of priority of United States Provisional Patent Application No. 61/365,188, filed July 16, 2010, which is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made with United States government support awarded by the United States Department of Agriculture Food Safety Consortium grant number 2010- 3421 1 -20961. The United States may have certain rights in this invention.
FIELD OF THE INVENTION
The present invention relates in general to methods for improving the health of agricultural animals. In particular, the present invention relates to bacterial isolates, probiotic formulations comprising the isolates and methods selecting and of using the probiotic formulations and isolates to improve the health of poultry.
BACKGROUND OF THE INVENTION
The use of antibiotics in animal agriculture, in particular poultry production, is coming under increasing pressure from both consumers and government regulatory agencies. This has created a need for effective antibiotic alternatives. The use of effective probiotics or direct-fed microbials (DFM) in animal agriculture may be one such potential alternative. Presently there are two general subsets of bacteria used in probiotic or DFM applications: lactic acid bacteria and Bacillus spp..
While some isolates are proven effective, lactic acid bacteria have the disadvantage that they must be applied through the drinking water. This is because these types of organisms are generally not tolerant of the heat needed to pellet many animal feed diets. Additionally, since these products must be applied through the water, the individual farmer is responsible for applying the product. This often leads to issues of compliance with proper administration guidelines leading to improper application and reduced efficacy of these products.
SUMMARY OF THE INVENTION
Methods for improving the gastrointestinal tract health in animals, bacterial isolates and probiotic formulations comprising these isolates arc provided herein. The bacterial isolates are Bacillus spp. selected from environmental sources that are capable of improving the health of poultry. These isolates were selected for their ability to 1) reduce Salmonella or other food-bome bacteria pathogenic to humans, 2) improve production parameters in commercial poultry operations, or 3) reduce enteric poultry bacterial pathogens. No known Bacillus DFM product, Bacillus isolate, or combination of Bacillus isolates are able to accomplish al l three tasks.
In one aspect, methods for improving gastrointestinal tract health in animals are provided. The methods include administering an endospore-forming bacterium to an animal. The endospore-forming bacteria are capable of reducing the number or growth of bacterial pathogens in the gastrointestinal tract of the animal. In addition, administration of the endospore-forming bacterium to the animal improves at least one production parameter in the animal.
In another aspect, bacterial isolates selected using the methods disclosed herein are provided and include Bacillus subtilis AM0904 (ATCC Deposit Number ###-###), Bacillus subtilis AM0911 (ATCC Deposit Number ###-###), Bacillus subtilis NP122 (ATCC Deposit Number ###-###), Bacillus subtilis ΝΡΠ 9Β (ATCC Deposit Number ###-###), B. licheniformis B l (ATCC Deposit Number ###-###), B. subtilis B2 (ATCC Deposit Number ###-###), B. licheniformis W25 (ATCC Deposit Number ###-###), B. licheniformis RW32 (ATCC Deposit Number ###-###), and B. licheniformis RW41 (ATCC Deposit Number ###-###).
In yet another aspect, multi-isblate combinations and probiotic compositions of the bacterial isolates disclosed herein are provided. In one embodiment, a combination of B. subtilis (one or more distinct isolates or strains) and/or B. licheniformis (at least one isolate) is provided. The bacterial isolates and probiotic formulations provided here improve upon current technology because they increase performance of commercial poultry, diminish common bacterial pathogens from within the gut of commercial poultry, and reduce common food-borne illness-associated bacteria, such as Salmonella, from within the gut of commercial poultry.
In a further aspect, animal feed comprising the probiotic compositions or bacterial isolates disclosed herein is provided. The feed may comprise between about 104 and 109 cfu/gm finished feed.
In still another aspect, methods for improving poultry health are provided. The methods include administration of the probiotic formulation or the animal feed described herein to an animal. The gastrointestinal health of the animal may be improved by the method.
In a still further aspect, methods of selecting bacterial strains for use in probiotic formulations are provided. The methods include selecting facultative anaerobic bacterial strains capable of forming endospores, selecting bacterial strains capable of reducing growth of pathogenic bacteria such as Salmonella enteritidis, Salmonella iyphinmrium, Campylobacter jejuni or Clostridium perfringens in mixed cultures in vitro or in the gastrointestinal tract of animals, selecting bacterial strains capable of improving the growth rate of commercial poultry, reducing the severity of necrotic enteritis and/or persisting in the gastrointestinal tract of poultry and removing any selected bacterial strains not considered GRAS (Generally Regarded As Safe) by the Food and Drug Administration (FDA), not eligible for inclusion into animal feed by the Association of American Feed Control Officials (AAFCO) or capable of hemolysis of sheep red blood cells.
BRIEF DESCRIPTION OF THE DRAWINGS
A more complete understanding of the present invention may be derived by referring to the detailed description and claims when considered in connection with the Figures.
Figure 1 is a diagram of the in vitro portion of the isolate selection procedures used to isolate and select candidate probiotic DFM isolates.
Figure 2 is a diagram of the in vivo portion of the isolate selection procedures used to isolate and select candidate probiotic DFM isolates. DETAILED DESCRIPTION
Methods, compositions and bacterial isolates for improved gastrointestinal health of poultry are disclosed. The compositions include probiotic formulations or Direct-Fed Microbials (DFM) and animal feed products. Methods of administration to improve animal health and reduce contamination of the human food chain and methods for isolating specific bacterial strains useful in the methods are also disclosed. The methods and compositions provided herein also produce greater consistency of production parameters within a group of animals.
Methods for improving gastrointestinal tract health in animals include administering an endospore-forming bacterium to an animal. The bacteria may be administered as spores, but need not be. The endospore-forming bacteria are capable of reducing the ability of bacterial pathogens to grow in the gastrointestinal tract of the animal. The number of bacterial pathogens found within the gastrointestinal tract is reduced in animals administered the endospore-forming bacteria as compared to control animals not administered the bacteria. Bacterial pathogens refers to bacteria capable of causing disease i.e., morbidity or mortality, in either the animal being administered the bacteria or humans. Pathogenic bacteria also include those bacteria capable of causing food-borne illness in humans.
The endospore-forming bacteria can be any bacteria capable of sporulation such as those of the genus Bacillus, in particular Bacillus subtilis or Bacillus licheniformis. The endospore-forming bacteria are suitably not pathogenic, i.e., they are not capable of causing morbidity or mortality in the animals being treated. Suitably the bacteria are facultative anaerobes and capable of replicating and/or persisting within the gastrointestinal tract of the animal. Suitably, the bacteria are Generally Regarded as Safe (GRAS) by the U.S. Food and Drug Administration (FDA) and acceptable for inclusion in an animal diet or water by the Association of American Feed Control Officials (AAFCO). Suitably the endospore-forming bacteria are not capable of causing hemolysis when incubated with or grown on media containing red blood cells. Suitably the endospore-forming bacteria are capable of reducing the growth of at least one pathogenic bacterium.
Administration of the bacteria improves the gastrointestinal health of the animal. The gastrointestinal health includes the prevention of disease of the, gastrointestinal tract itself, such as necrotic enteritis of the intestines, or the pathogenic bacterial load of the intestines, ceca or lower intestine, and increase in production parameters for the treated animals as compared to controls. Production parameters include but arc not limited to average daily weight gain, feed conversion rates, consistency of growth among a group of animals, ability to reproduce and bear healthy offspring, ability to produce eggs or milk and the quantity and quality of such production.
In accordance with one aspect, an exemplary composition or formulation can include one or more bacteria capable of forming endospores. Bacteria capable of forming endospores include bacteria of the genus Bacillus. Specific B. subtilis and B. Hcheniformis bacterial isolates are disclosed herein, but other endospore forming bacteria suitable for use in the methods and compositions disclosed herein can be isolated and selected by those of skill in the art using the methods of selection described below and in the Examples. For example, a composition can comprise a formulation containing one or two different isolates of B. subtilis and/or one or two isolates of B. lichen iformis, wherein each isolate is independently selected to perform a specific role and/or function. The combination of these isolates can be combined with an agricultural animal feed (specifically poultry feed) and ultimately used to improve the health and productivity of the agricultural animals (e.g. livestock and/or poultry). For example the isolates and/or the combined isolate formulations can reduce pathogenic bacteria, in particular food- borne illness associated bacteria, that cause the eggs or meat to be contaminated, can reduce gut pathogens in the poultry, and increase weight gain or egg production of commercial poultry.
Specifically, the isolates can decrease the occurrence or load of at least one of Salmonella, Campylobacter and Clostridium. Through the reduction of C. perfringens in the gastrointestinal tract of the agricultural animals and through other beneficial reactions of the isolates with the agricultural animals, the occurrence of necrotic enteritis is reduced. In addition, reducing these bacteria decreases the mortality rate of the agricultural animals, and the average daily weight gain of the agricultural animals is increased. In the case of poultry, a reduced level of Salmonella within the
gastrointestinal tract may lead to less carcass contamination as well as reduce the likelihood of Salmonella contaminated eggs.
As described in the examples below, the bacterial isolates were selected for their ability to form spores and as such are resistant to temperature extremes. The selected bacteria are facultative anaerobes and are not hemolytic. The bacteria are capable of inhibiting or reducing the growth of both gram positive and gram negative bacteria such as Salmonella, Clostridium and Campylobacter. The ability to reduce pathogenic bacterial growth allows the selected bacteria to reduce necrotic enteritis in poultry. The selected bacteria are also capable of increasing the growth rate and gastrointestinal health of commercial poultry and are capable of persisting and colonizing in the gastrointestinal tract of poultry. The isolates are all considered as GRAS (Generally recognized as safe) by the FDA and are eligible for inclusion in animal feed by the AAFCO. Furthermore, these particular isolates are able to go through their entire life cycle within the gastrointestinal tract of agricultural animals, specifically in commercial poultry.
The bacterial isolates identified in the Examples and capable of being used in probiotic formulations or in animal feed for use in the methods described herein are the following: Bacillus subtilis AM0904 (ATCC Deposit Number), Bacillus subtilis AM091 1 (ATCC Deposit Number), Bacillus subtilis NP 122 (ATCC Deposit Number), Bacillus subtilis NR1 19B (ATCC Deposit Number), licheniformis B l (ATCC Deposit
Number), B. subtilis B2 (ATCC Deposit Number), B. licheniformis RW25 (ATCC Deposit Number), B. licheniformis RW32 (ATCC Deposit Number), and B. licheniformis RW41 (ATCC Deposit Number).
The spore, or inert, survival form of Bacillus spp. do not produce any known effectors which may reduce bacterial pathogens in the gastrointestinal tract or have other beneficial effects on the animal. In contrast, the vegetative form of the bacteria can produce effectors. Thus, reactivation and germination of the spores after administration is likely important to the improvement of poultry gastrointestinal health. The ability of Bacillus probiotic products to germinate within the gut of commercial poultry has not been adequately investigated. The bacterial isolates described herein were also selected for their ability to reactivate^ germinate and colonize or persist within animals after administration of spores of the bacteria to animals.
Probiotic formulations comprising at least one of the bacterial isolates provided herein are also disclosed. The probiotic formulation may comprise a combination of the bacterial isolates disclosed herein or may include bacterial isolates other than those disclosed herein. Suitably, the bacteria used are capable of forming endospores, are capable of reducing the pathogenic bacterial loads in the gastrointestinal tract and are capable of increasing at least one production parameter. For example, the probiotic formulation may include at least one Bacillus sublilis strain and/or at least one Bacillus lichemformis strain. In other examples, the probiotic formulation may include two or more Bacillus sublilis strains or two or more Bacillus lichemformis strains. The bacterial isolates may be used in any combination in the probiotic formulations. For example a combination of NP122 and B2 may be used. Alternatively, ΝΡ Γ22 and B2 may be used in combination with AM0904 or AM091 1. Any other possible combination of the bacterial isolates provided herein may also be made.
The ratio of one isolate to another in a combination probiotic formulation can vary within a wide range. Suitably the ratio of bacterial isolates is between 0.1 : 1 and 10: 1 , suitably between 0.5: 1 and 5: 1 , more suitably 1 : 1 to 3: 1 , more suitably it is between 1 : 1 and 2: 1. In one embodiment the ratio of NP 122 to B2 to AM0904 was 5:5: 1. The ratios are based on the colony forming units (cfu) of the bacterial spores after reactivation. ,
The probiotic formulation is capable of improving the health of animals after administration to animals. In particular, the probiotic formulation or animal feed comprising the probiotic formulation is capable of improving the gastrointestinal health of poultry. This may include reducing the incidence or severity of necrotic enteritis (by at least 10%, 15% or even 20% as compared to controls and mortality may be prevented), reducing the bacterial load in the intestines of the animal, specifically with regards to levels of at least one of Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry (at least 50% decrease in recovery, suitably at least 60%, 70%, 80%, 90% or even more of a decrease in recovery as compared to controls), and increasing the daily average weight gain of an animal (at least a 3% increase suitably at least a 5%, 7%, 10%, 20%, 30% 40%, 50%, 55%, 60% or even more increase in weight gain as compared to controls (measured as average daily weight gain)). The feed conversion rate may also be increased as compared to controls. For example the feed conversion rate may be increased by 2%, 3%, 5%, 7%, 10% or more.
Administration of the probiotic formulation may also reduce the level or number of potential bacterial food-borne pathogens of humans in the gastrointestinal tract of commercial poultry. In particular the level of Salmonella and Campylobacter spp. in the gastrointestinal tract of animals administered the probiotic formulation may be reduced as compared to control animals not administered the probiotic or the spore-forming bacteria. Such a reduction in potential human pathogen load in the gastrointestinal tract of poultry will limit the opportunity of contaminating the human food chain either during preparation of meat for human consumption or via contamination of poultry eggs or milk.
These isolates, probiotic formulations comprising the isolates or animal feed comprising the isolates or combinations thereof may be administered to animals orally. Oral administration includes, but is not limited to, delivery in feed, water, by oral gavage or aerosol spray. Suitably the animal is a poultry, more suitably a chicken or turkey. If supplied in an animal feed, the feed may comprise between 104 and 109 cfu bacteria/gm of finished feed. Suitably the feed comprises between 105 and 5 x 107 cfu bacteria/gm feed. The probiotic formulation may be added to the feed during production, after production by the supplier or by the person feeding the animals, just prior to providing the food to the animals. The endospore-forming bacteria used in the methods and compositions described herein are particularly suitable because they are capable of surviving (as spores) the heat and pressure conditions of the process of producing a dry pelleted feed product.
These isolates or isolate combinations for inclusion in the methods and including those isolates selected and described in the Examples are selected for inclusion in agricultural animal diets to increase overall gastrointestinal health, improve production performance, and reduce enteric bacterial pathogens of importance to both animal health and human food safety. These isolates alone or in combination may be added to poultry diets at the rate of about 104 to 109 (l . lx l07 in the Examples) spores per gram of finished feed for optimal inclusion rate, if the bacteria or probiotic compositions being administered continuously. A higher inclusion rate may be necessary if spores of the bacteria or the compositions are provided intermittently. While administration though the feed is the primary route of administration, the spores of these isolates may also be administered via the drinking water, through course spray, through aerosol spray, or through any other means by which the agricultural animals may ingest these isolates or combination of isolates. Methods of isolating bacteria strains for inclusion in probiotic formulations are also provided herein and are depicted in Figures 1 and 2. The methods include both in vitro and in vivo tests to select bacteria from a source and may be completed in any order. Sources of potential bacterial isolates include animal feces, environmental or soil samples, laboratory stocks of bacteria from tissue and cell supply warehouses such as the American Type Culture Collection (ATCC). The bacteria may then be isolated and selected by selecting facultative anaerobic bacterial strains capable of forming spores; capable of reducing the growth of or killing Salmonella enteritidis, Salmonella typhimurium, Campylobacter jejuni and/or Clostridium perfringens; capable of improving growth rate of commercial poultry; capable of reducing the severity of necrotic enteritis; capable of persisting in the gastrointestinal tract of poultry. The methods also include removing bacterial strains not considered GRAS by the FDA, not cligblc for inclusion into animal feed by AAFCO or those capable of hemolysis.
Bacterial strains fitting these criteria may then be included in probiotic formulations.
The present invention sets forth exemplary isolates, compositions, and methods for improving GI tract health in animals. It will be understood that the description is of exemplary embodiments of the invention, and that the invention is not limited to the specific forms shown. Various modifications may be made in the design and
arrangement of the elements set forth herein without departing from the scope of the invention. For example, the various components can be used in various combinations in addition to those illustrated in the exemplary embodiments, and the various steps can be conducted in different orders. These and other changes or modifications are intended to be included within the scope of the present invention Examples
Environmental samples or poultry fecal samples were collected using sterile cotton swabs and placed into a sterile borosilicate tube for transport. An outline of the in vitro tests used to select bacterial isolates is depicted in Figure 1. The swabs were either immersed in 50% ethanol or heated to 70°C for 15 min prior to being used to inoculate tryptic soy agar (TSA) and Spizizen potato agar (SPA) to select for Bacillus spp. After incubation for 24 h and 72 h respectively at 37°C, the resulting cultures were overlaid with a TSA soft agar containing novobiocin (NO) at 25 μg ml and 106 cfu/ml Salmonella enterica serovar Enteritidis phage type 13A (SE) originally obtained from the U.S.
Department of Agriculture National Veterinary Services Laboratory. After incubation, those colonies which produced zones of inhibition in the SE overlay were selected for isolation. The selected colonies were pasteurized in 50% ethanol for 30 minutes then isolated on the same medium from which they were selected and incubated for cither 24 h (TSA) or 72 h (SPA) at 37°C. The isolates ability to inhibit growth of SE was confirmed using a second SE overlay. Those isolates with confirmed in vitro ability to inhibit SE growth were amplified and selected for further analysis.
TSA plates containing sheep blood were inoculated with the isolates and incubated for 24 h at 37°C. The plates were then evaluated and scored for level of hemolysis. All isolates causing alpha or beta hemolysis were not evaluated further. Similarly, further testing of any isolate whose colony morphology was consistent with that of the B. cere s group (B. cereus, B. mycoides, B. thurigensis, and B. anthrasis) was discontinued. Those isolates with the greatest in vitro antimicrobial activity (anti-SE) were identified using the bioMerieux API 50 CHB test kit. The Bacillus isolates identified using the above methods were further screened for in vitro microbial inhibitory activity "for Clostridium perfringen (CP) and Campylobacter jejuni. A similar overlay method as described above was used, but overlays were incubated anaerobically and NO was not added to the overlay media.
In an effort to grow high numbers of viable spores, a solid state fermentation media was used. Only isolates which were able to grow and sporulate to greater than lxl O10 spores per gram were selected for further evaluation. Three samples of each of the sporulated candidate cultures were diluted 1 :9 in 0.9% sterile saline. Duplicate samples were subjected to room temperature for 30 min or 100°C for 10 min to assess heat stability of the candidate spores. Following the heat treatments, the spore solutions were diluted, plated and incubated overnight at 37°C on TSA plates for colony forming unit determination. Only isolates whose spores lost less than 1 logio unit after heat treatment were further evaluated.
Isolates which passed the in vitro testing were evaluated using a series of in vivo tests illustrated in Figure 2. These isolates were selected for further analysis in in vivo trials with poults and chicks due to their performance in the // vitro tests. An antibiotic- free corn-soy turkey starter diet produced by the University of Arkansas Department of Poultry Science feed mill (Fayetteville, AR 72701 ) and formulated to meet or exceed the National Research Council requirements for critical nutrients of young poults and chicks was used as the basal diet for these experiments. Spores from the candidate isolates were added to the basal diet at a concentration of about 106 cfu/gm of feed and mixed with a rotary mixer for 15 minutes to distribute spores throughout feed. Commercial broiler chicks and commercial turkeys were obtained on day of hatch and orally gavaged with Salmonella lyphimurium (ST) at a dose of about 1 Oscfu/chick. They were then randomly assigned to groups: negative control (basal diet) or a group fed the basal diet containing spores of one of the candidate isolates (n=20/group). The poults and chicks were then tagged, weighed, and placed into the appropriate floor pens by treatment. The poults and chicks had fresh pine shaving as bedding material and had free access to feed and water throughout the duration of the trial. At the conclusion of the trial, on or about day 10, the chicks and poults were weighed. The cecal tonsils were aseptically removed and placed into tetrathionate broth. The ceca were homogenized and diluted 1 :4 by weight with sterile saline. Total viable counts of ST were determined by plating dilutions on BGA plates with NO (25μg mL) and nalidixic acid (NA; 2( g mL) after 24 h of incubation at 37°C. The plates were examined for the presence of colonies typical of this strain of ST on BGA media. Isolates which produced body weight gains greater than control and led to a decreased recovery of ST were selected for further testing, while unsuccessful isolates were discarded.
Successful isolates from the above test were again incorporated in a poultry ration as described above. Spores from the candidate isolates were added to the basal diet and mixed with a rotary mixer for 15 minutes to distribute spores throughout feed.
Commercial broiler chicks were obtained on day of hatch and orally gavaged with
Salmonella typhimurhim (ST). They were then randomly assigned to groups: negative control (basal diet) or a group fed the basal diet containing spores of one of the candidate isolates. The chicks were then tagged, weighed, and placed into the appropriate floor pens by treatment group (n= 20/group). The chicks had fresh pine shaving as bedding material and had free access to feed and water throughout the duration of the trial. At
approximately 3 weeks of the age all chicks were weighed then orally gavaged with
Ei eria maxima (EM). On days 3-5 post challenge with EM all chicks were challenged with Clostridium perfringens. On or about 4 weeks of age all chicks were weighed and the chicks intestines were assigned a subjective score for necrotic enteritis lesions as previously described (Avian Diseases 51 (4):834-839 (2007)). Isolates which
significantly reduced (p<0.5) the severity of necrotic enteritis were kept for further evaluation.
In a subsequent test, all successful isolates were evaluated for their ability to persist within the gastrointestinal tract of commercial poultry. Commercial broiler chicks were obtained on day of hatch them randomly separated into groups. These chicks were placed by group into isolator units. The chicks were fed a standard broiler starter ration which had previously been heat sterilized. On or about day 7, the individual groups (n=20) of broiler chicks were orally gavaged with about 109 cfu of the candidate isolates or sterile saline (as a negative control). The persistence of the candidate isolates was evaluated by enumerating ingesta from individual birds in most experiments. Many of the tested isolates declined in numbers markedly such that by 72 hours post-gavage, cfu of less than 1 x 103 cfu/gm ingesta were enumerated, declining similarly to an expected gut passage time of approximately 4-6 hours, indicating that these isolates were not replicating within the gastrointestinal tract. However, some isolates were recovered at levels of greater than IxlO5 cfu/gm at 96 hours post-gavage. Such isolates were selected for further evaluation. Isolates which persisted longer than their predicted half life were selected for continued evaluation. Using the selection processes a total of nine isolates were found to be potentially useful, alone or in combination with other isolates, as a probiotic or DFM for use in commercial poultry. These nine isolates include Bacillus snbtilis strains AM0904 (ATCC Deposit Number ###-###), AM091 1 (ATCC Deposit Number ###-###), NP 122 (ATCC Deposit Number ###-###), and NPl 19B (ATCC Deposit Number ###-###) and B. licheniformis strains to include B l (ATCC Deposit Number ###-###), B2 (ATCC Deposit Number ###-#&#), RW25 (ATCC Deposit Number ###-###), RW32 (ATCC Deposit Number ###-###), and RW41 (ATCC Deposit Number ###-###).
In a final series of testing, the isolates were retested not as individual isolates, but in combinations of 2 to 3 isolates. These combinations were subjected to the
aforementioned in vivo tests and evaluated using the same parameters stated above, as well as compared to the performance of the individual isolates in these same tests. The best performing isolates and isolate combinations were used further in field testing and were considered as potential candidates for inclusion in a final product.
Combinations of the above listed isolates may include, but are not limited to, the following: NP l 22, AM0904, and B2. This combination has been shown to be effective when administered in the ratio of 5:5: 1 for isolates NP122, B2 and AM0904 respectively. When administered in the feed this combination has been show to be effective to yield significant (p<0.05) reduction of Salmonella infection (50-90% decrease in recovery), necrotic enteritis mortality and lesions (22% in controls to 0% in treated), and improving body weight gain during challenge periods by more than 50% when administered at the rate of 5x l06: 5xl 06: lx lO6: spores per gram of finished feed for isolates NPl 22, B2 and AM0904, respectively.

Claims

CLAIMS What is claimed is:
1. A method for improving gastrointestinal tract health in animals comprising: administering an endospore-forming bacterium to an animal, wherein the bacterium is capable of reducing growth of a bacterial pathogen in the gastrointestinal tract of the animal and wherein administration of the spore-forming bacterium to the animal improves at least one production parameter in the animal.
2. The method of claim 1 , wherein the endospore-forming bacterium is administered as an endospore comprised within a dry pelleted animal feed.
3. The method of any one of the preceding claims wherein the bacterial pathogen is a bacterium capable of causing disease in a human.
4. The method of claim 3, wherein the bacterial pathogen is selected from
Salmonella, Campylobacter or Clostridium.
5. The method of any one of the preceding claims, wherein the bacterial pathogen is a bacterium capable of causing disease in poultry.
6. The method of any one of the preceding claims, wherein the endospore-forming bacterium is administered via the animal feed.
7. The method of any one of the preceding claims, wherein the endospore-forming bacterium is capable of surviving animal feed processing.
8. The method of any one of the preceding claims, wherein the endospore-forming bacterium is comprised within a probiotic formulation.
9. The method of any one of the preceding claims, wherein the animals are poultry.
10. The method of any one of the preceding claims, wherein the production parameter is selected from increasing the daily weight gain of the animal, decreasing morbidity or mortality of the animal from any cause, or decreasing morbidity or mortality of the animal from bacterial pathogens.
1 1. The method of any one of the preceding claims, wherein the spore-forming bacterium comprises at least one of BaciUus subiilis AM0904 (ATCC Deposit Number ###-###), Bacillus subiilis A 091 1 (ATCC Deposit Number ###-###), Bacillus subiilis NP122 (ATCC Deposit Number ###-###), Bacillus subiilis NP1 19B (ATCC Deposit Number ###-###), B. lichemformis Bl (ATCC Deposit Number ###-###), B. subiilis B2 (ATCC Deposit Number ###-###), B. lichemformis RW25 (ATCC Deposit Number ###- ###), B. lichemformis RW32 (ATCC Deposit Number ###-###), or B. lichemformis RW41 (ATCC Deposit Number ###-###).
12. A bacterial isolate selected from the group of Bacillus subiilis AM0904 (ATCC Deposit Number ###-###), Bacillus subiilis AM091 1 (ATCC Deposit Number ###-###), Bacillus subiilis NP122 (ATCC Deposit Number ###-###), Bacillus subiilis NP1 19B (ATCC Deposit Number ###-###), B. lichemformis B l (ATCC Deposit Number ###- ###), B. subiilis B2 (ATCC Deposit Number ###-###), B. lichemformis RW25 (ATCC Deposit Number ###-###), B. lichemformis RW32 (ATCC Deposit Number ###-###), and B. lichemformis RW41 (ATCC Deposit Number ###-###).
13. A probiotic formulation comprising at least one of the bacterial isolates of claim 12.
14. The probiotic formulation of claim 13, wherein the bacterial isolate is capable of improving gastrointestinal tract health in poultry.
15. The probiotic formulation of claim 14, wherein improving the gastrointestirial tract comprises reducing potential bacterial food-borne pathogens of humans from the gastrointestinal tract of commercial poultry.
16. The probiotic formulation of claim 14, wherein improving gastrointestirial health in poultry comprises reducing at least one of Salmonella, Campylobacter or Clostridium perfringens in the gastrointestinal tract of poultry.
17. The probiotic formulation of claim 14, wherein improving gastrointestinal health in poultry further comprises increasing the daily weight gain of the poultry.
18. The probiotic formulation of claim 15, wherein reducing potential bacterial food- borne pathogens of humans from the gastrointestinal tract of commercial poultry comprises reducing Salmonella in the gastrointestinal tract of poultry.
1 . The probiotic formulation of any one of claims 13-18, wherein the formulation comprises at least one Bacillus subtilis isolate and at least one Bacillus licheniforinis isolate.
20: The probiotic formulation of claim 19, further comprising a second Bacillu subtilis isolate:
21. The probiotic formulation of claim 19 or 20, wherein the ratio of Bacillus subtilis to Bacillus licheniformis is between 0.5: 1 and 3: 1.
22. The probiotic formulation of claim 20, wherein the Bacillus subtilis isolates comprise NP 122, AM0904 or B2.
23. The probiotic formulation of claim 22, wherein the strains are present in a ratio of about 5: 5: 1 for NP122, B2 and AM0904.
24. The probiotic formulation of any of claims 13-23, wherein the formulation is configured to be administered via an agricultural animal feed substrate.
25. An animal feed comprising the probiotic formulation of any of claims 13-24, wherein the feed comprises between 104 and 109 cfu/gm finished feed.
26. A method for improving gastrointestinal tract health in poultry comprising:
administering the probiotic formulation of any of claims 13-24 or the animal feed of claim 24 to an animal.
27. The method of claim 26, wherein the probiotic formulation is administered orally.
28. The method of claim 27, wherein oral administration includes delivery via feed, water, oral gavage, or aerosol spray.
29. The method of any of claims 26-28, wherein the animal is poultry.
30. A method for selecting bacterial strains for use in a probiotic formulation for improving the gastrointestinal health of poultry, comprising:
selecting facultative anaerobic bacterial strains capable of forming spores;
selecti ng bacterial strains capable of reducing growth of at least one of Salmonella enteritidis, Salmonella lyphimuriuin, Campylobacler jejuni or Clostridium perfringens;
selecting bacterial strains capable of improving growth rate of commercial poultry or capable of reducing severity of necrotic enteritis or capable of persisting in the gastrointestinal tract of poultry; and
removing bacterial strains not considered GRAS by the FDA, not eligible for inclusion into animal feed by AAFCO (Association Of American Feed Control Officials) or capable of hemolysis
for use in a probiotic formulation.
PCT/US2011/044326 2010-07-16 2011-07-18 Methods and compositions including spore-forming bacteria for increasing the health of animals WO2012009712A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/810,549 US9005601B2 (en) 2010-07-16 2011-07-18 Methods and compositions including spore-forming bacteria for increasing the health of animals
BR112013001107-6A BR112013001107B1 (en) 2010-07-16 2011-07-18 Methods and compositions including spore-forming bacteria for enhancing animal health
EP11807617.3A EP2593187A4 (en) 2010-07-16 2011-07-18 Methods and compositions including spore-forming bacteria for increasing the health of animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36518810P 2010-07-16 2010-07-16
US61/365,188 2010-07-16

Publications (2)

Publication Number Publication Date
WO2012009712A2 true WO2012009712A2 (en) 2012-01-19
WO2012009712A3 WO2012009712A3 (en) 2012-05-10

Family

ID=45470116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/044326 WO2012009712A2 (en) 2010-07-16 2011-07-18 Methods and compositions including spore-forming bacteria for increasing the health of animals

Country Status (4)

Country Link
US (1) US9005601B2 (en)
EP (1) EP2593187A4 (en)
BR (1) BR112013001107B1 (en)
WO (1) WO2012009712A2 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022572A1 (en) * 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9011834B1 (en) 2013-02-04 2015-04-21 Seres Health, Inc. Compositions and methods
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
WO2016060934A1 (en) * 2014-10-08 2016-04-21 Novozymes A/S Bacillus strains with fast germination and antimicrobial activity against clostridium perfringens
CN106714570A (en) * 2014-05-13 2017-05-24 微生物发现集团有限责任公司 Direct-fed microbials and methods of their use
WO2017132230A1 (en) * 2016-01-25 2017-08-03 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
WO2018167171A1 (en) * 2017-03-14 2018-09-20 Chr. Hansen A/S Bacillus subtilis strains improving animal performance parameters
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
WO2021146582A1 (en) * 2020-01-17 2021-07-22 AgBiome, Inc. Compositions and methods for controlling undesirable microbes and improving animal health
US11110134B2 (en) 2016-02-29 2021-09-07 Microbial Discovery Group, Llc Direct-fed microbials
US11166989B2 (en) 2015-01-23 2021-11-09 Novozymes A/S Bacillus strains improving health and performance of production animals
US11331351B2 (en) 2015-01-23 2022-05-17 Novozymes A/S Bacillus strains improving health and performance of production animals
US11473052B2 (en) 2015-01-23 2022-10-18 Novozymes A/S Bacillus subtilis subspecies
US11627741B2 (en) 2018-09-28 2023-04-18 Microbial Discovery Group, Llc Microorganisms for plant pathogen inhibition
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10716310B2 (en) 2014-03-13 2020-07-21 Phibro Animal Health Corporation Strains of bacillus for inhibiting foodborne pathogens
MX2018000500A (en) * 2015-07-14 2018-11-12 Univ Arkansas Compositions, probiotic formulations and methods to promote digestion and improve nutrition in poultry.
US11771065B2 (en) * 2015-08-20 2023-10-03 Api Holdings, Llc Formulations and methods for promoting honeybee health
US10201574B1 (en) 2015-09-16 2019-02-12 Church & Dwight Co., Inc. Methods of microbial treatment of poultry
ES2759360T3 (en) 2015-10-09 2020-05-08 Axichem Ab Feed for poultry, and in particular feed for poultry, comprising synthetic capsaicinoid derivatives and feed of this type for prophylactic use or treatment of salmonella infection
US11298383B2 (en) 2016-05-20 2022-04-12 Church & Dwight Co., Inc. Lactobacillus and bacillus based direct fed microbial treatment for poultry and method of use
BR112018074133A2 (en) 2016-05-25 2019-03-06 Church & Dwight Co., Inc. Bacillus compositions and methods of use with ruminants
US11622569B2 (en) 2017-07-24 2023-04-11 Church & Dwight Co., Inc. Bacillus microbial terroir for pathogen control in swine
BR112020014513A2 (en) 2018-01-24 2021-01-12 OmniGen Research, L.L.C. BACILLUS COMBINATION FOR ADMINISTRATION TO ANIMALS
MX2023005934A (en) * 2020-11-23 2023-08-09 Univ Ljubljani Strain with strong inhibition of enteropathogenic and foodborne pathogenic bacteria.
CN113892563B (en) * 2021-09-18 2023-08-25 江苏农林职业技术学院 Composite probiotic preparation for relieving cold stress

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092428A1 (en) * 2008-09-17 2010-04-15 Joseph Earl Schmidt Method For Using A Bacillus Subtilis Strain To Enhance Animal Health
US7754469B2 (en) * 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335107A (en) 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
FI59925C (en) 1980-01-11 1981-11-10 Esko Viljo Nurmi FOERFARANDE FOER FRAMSTAELLNING AV ETT BAKTERIEPREPARAT ANVAENDBART FOER FOERHINDRANDE AV SALMONELLAINFEKTION HOS FJAEDERFAE
FI840816A0 (en) 1984-03-01 1984-03-01 Farmos Oy BAKTERIEPREPARAT
JPH01502340A (en) 1987-02-24 1989-08-17 インスティテュト　ミクロビオロギイ　イ　ビルソロギイ　イメニ　デー．カー．ザボロトノゴ　アカデミイ　ナウク　ウクラインスコイ　エスエスエル Preparations for the prevention and treatment of gastrointestinal diseases in livestock
US4910024A (en) 1988-07-05 1990-03-20 Micro Chemical, Inc. Method and apparatus for administering live bacteria as feed additives to livestock and poultry
CN1076586C (en) 1993-03-16 2001-12-26 美国政府农业部 Mucosal competitive exclusion flora
GB9416841D0 (en) 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
US6506389B2 (en) 1995-10-20 2003-01-14 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
US5807546A (en) 1996-10-11 1998-09-15 The United States Of America As Represented By The Secretary Of Agriculture Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria
US6017525A (en) 1997-04-02 2000-01-25 Logan; Walter T. Poultry house litter treatment
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6110455A (en) 1999-01-20 2000-08-29 Ms Bioscience Method for encouraging poultry to distribute and ingest competitive exclusion products
DE10105347A1 (en) 2001-02-05 2002-08-22 Nutrinova Gmbh Sorbic acid preparation containing probiotics as a feed additive in livestock rearing
RU2203947C1 (en) 2001-09-26 2003-05-10 Закрытое акционерное общество "КУЛ" Strain of bacterium bacillus licheniformis used for preparing probiotic preparation designated for prophylaxis and treatment of gastroenteric diseases in animals, poultry and fishes
EP1314359A1 (en) 2001-11-21 2003-05-28 N.V. Seghers Nutrition Sciences Growth promoter composition for animals
EP1556479A4 (en) 2002-07-22 2006-04-05 Agtech Products Inc Lactobacillus strains and uses therefor
RU2252956C2 (en) 2002-11-11 2005-05-27 Закрытое акционерное общество "КУЛ" Probiotic additive and method for production thereof
US7247299B2 (en) 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US20040241150A1 (en) 2002-12-19 2004-12-02 Hargis Billy M. Defined competitive exclusion cultures for food borne pathogens
CA2559183A1 (en) * 2003-03-11 2004-09-23 Inatech International Inc. Probiotic micro-organisms and uses thereof
US20050271643A1 (en) 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
US7700094B1 (en) 2003-09-23 2010-04-20 Pioneer Hi-Bred International, Inc. Acetyl esterase producing strains and methods of using same
US20100074873A1 (en) 2004-05-25 2010-03-25 Watson James B Live bacteria product
EP1967196A4 (en) 2005-11-18 2009-10-14 Idemitsu Kosan Co Harmful bacterium control agent containing bacillus thuringiensis
US20080057047A1 (en) 2005-11-29 2008-03-06 Benedikt Sas Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
US20080044501A1 (en) 2006-08-16 2008-02-21 Genebiotech Co. Ltd. Fermented soybean products and methods of producing them
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
ES2387623T3 (en) 2007-07-06 2012-09-27 Chr. Hansen A/S Bile resistant bacillus composition with high levels of phytase secretion
CN101580799B (en) 2008-05-14 2011-01-12 北京大北农科技集团股份有限公司 Micro-ecological preparation and application thereof
US8227235B2 (en) 2008-12-10 2012-07-24 Alpharma, Llc Compositions and methods for controlling diseases in animals
CN101569375A (en) 2009-06-05 2009-11-04 李守凡 Novel biological feed for cattle
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US9023345B2 (en) 2011-03-01 2015-05-05 Novus International, Inc. Methods for improving gut health
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754469B2 (en) * 2005-11-30 2010-07-13 Agtech Products, Inc Microorganisms and methods for treating poultry
US20100092428A1 (en) * 2008-09-17 2010-04-15 Joseph Earl Schmidt Method For Using A Bacillus Subtilis Strain To Enhance Animal Health

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2593187A2 *
WOLFENDEN, R.: 'Evaluation of selected antibiotic alternatives for control of enteric bacterial pathogens of commercial poultry.' EVALUATION OF SELECTED ANTIBIOTIC ALTERNATIVES FOR CONTROL OF ENTERIC BACTERIAL PATHOGENS OF COMMERCIAL POULTRY., [Online] May 2010, XP055082826 Retrieved from the Internet: <URL:http://search.proquest.com/docview/375 356802? accountid=142944> [retrieved on 2012-02-22] *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005601B2 (en) 2010-07-16 2015-04-14 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US9107938B2 (en) 2010-09-30 2015-08-18 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US9393275B2 (en) 2012-08-01 2016-07-19 Novozymes A/S Probiotic for amelioration of coccidiosis vaccine reaction
WO2014022572A1 (en) * 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
US10864235B2 (en) 2012-11-23 2020-12-15 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11464812B2 (en) 2012-11-23 2022-10-11 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9028841B2 (en) 2012-11-23 2015-05-12 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458174B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11458173B2 (en) 2012-11-23 2022-10-04 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11389490B2 (en) 2012-11-23 2022-07-19 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9533014B2 (en) 2012-11-23 2017-01-03 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9585921B2 (en) 2013-02-04 2017-03-07 Seres Therapeutics, Inc. Compositions and methods
US10967011B2 (en) 2013-02-04 2021-04-06 Seres Therapeutics, Inc. Compositions and methods
US9855303B2 (en) 2013-02-04 2018-01-02 Seres Therapeutics, Inc. Compositions and methods
US11185562B2 (en) 2013-02-04 2021-11-30 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
US10064901B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Compositions and methods
US10064900B2 (en) 2013-02-04 2018-09-04 Seres Therapeutics, Inc. Methods of populating a gastrointestinal tract
US9446080B2 (en) 2013-02-04 2016-09-20 Seres Therapeutics, Inc. Compositions and methods
US9180147B2 (en) 2013-02-04 2015-11-10 Seres Therapeutics, Inc. Compositions and methods
US9011834B1 (en) 2013-02-04 2015-04-21 Seres Health, Inc. Compositions and methods
US11730775B2 (en) 2013-02-04 2023-08-22 Seres Therapeutics, Inc. Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US10076546B2 (en) 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US10881696B2 (en) 2013-03-15 2021-01-05 Seres Therapeutics, Inc. Network-based microbial compositions and methods
US11666612B2 (en) 2013-03-15 2023-06-06 Seres Therapeutics, Inc Network-based microbial compositions and methods
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11918612B2 (en) 2013-11-25 2024-03-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11266699B2 (en) 2013-11-25 2022-03-08 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10905135B2 (en) 2014-05-13 2021-02-02 Microbial Discovery Group, Llc Direct-fed microbials and methods of their use
CN106714570A (en) * 2014-05-13 2017-05-24 微生物发现集团有限责任公司 Direct-fed microbials and methods of their use
WO2016060934A1 (en) * 2014-10-08 2016-04-21 Novozymes A/S Bacillus strains with fast germination and antimicrobial activity against clostridium perfringens
US11166989B2 (en) 2015-01-23 2021-11-09 Novozymes A/S Bacillus strains improving health and performance of production animals
US11331351B2 (en) 2015-01-23 2022-05-17 Novozymes A/S Bacillus strains improving health and performance of production animals
US11473052B2 (en) 2015-01-23 2022-10-18 Novozymes A/S Bacillus subtilis subspecies
US11801272B2 (en) 2015-01-23 2023-10-31 Novozymes A/S Bacillus strains improving health and performance of production animals
US11395479B2 (en) 2016-01-25 2022-07-26 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
WO2017132230A1 (en) * 2016-01-25 2017-08-03 Novozymes A/S Method to reduce microbial bloom in poultry hatchery
US11110134B2 (en) 2016-02-29 2021-09-07 Microbial Discovery Group, Llc Direct-fed microbials
US11291695B2 (en) 2017-03-14 2022-04-05 Chr. Hansen A/S Bacillus subtilis strains improving animal performance parameters
CN110573606A (en) * 2017-03-14 2019-12-13 科·汉森有限公司 Bacillus subtilis strain for improving animal performance parameters
WO2018167171A1 (en) * 2017-03-14 2018-09-20 Chr. Hansen A/S Bacillus subtilis strains improving animal performance parameters
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
US11627741B2 (en) 2018-09-28 2023-04-18 Microbial Discovery Group, Llc Microorganisms for plant pathogen inhibition
WO2021146582A1 (en) * 2020-01-17 2021-07-22 AgBiome, Inc. Compositions and methods for controlling undesirable microbes and improving animal health

Also Published As

Publication number Publication date
US9005601B2 (en) 2015-04-14
US20130136695A1 (en) 2013-05-30
BR112013001107B1 (en) 2022-01-25
EP2593187A4 (en) 2014-04-09
WO2012009712A3 (en) 2012-05-10
BR112013001107A2 (en) 2020-08-04
EP2593187A2 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
US9005601B2 (en) Methods and compositions including spore-forming bacteria for increasing the health of animals
Stavric et al. 10 Microbial probiotics for pigs and poultry
Impey et al. Competitive exclusion of salmonellas from the chick caecum using a defined mixture of bacterial isolates from the caecal microflora of an adult bird
Shivaramaiah et al. Evaluation of Bacillus species as potential candidates for direct-fed microbials in commercial poultry
Latorre et al. Evaluation of germination, distribution, and persistence of Bacillus subtilis spores through the gastrointestinal tract of chickens
Kantas et al. A feed additive containing Bacillus toyonensis (Toyocerin®) protects against enteric pathogens in postweaning piglets
US20150104418A1 (en) Bacterial composition
US5458875A (en) In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
Wolfenden et al. Evaluation of a screening and selection method for Bacillus isolates for use as effective direct-fed microbials in commercial poultry
Wang et al. Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs
Zhang et al. Effect of a potential probiotics Lactococcus garvieae B301 on the growth performance, immune parameters and caecum microflora of broiler chickens
CA2100774C (en) Feed additive and method
Chaiyawan et al. Characterization and probiotic properties of Bacillus strains isolated from broiler
Jarquin et al. The evaluation of organic acids and probiotic cultures to reduce Salmonella enteriditis horizontal transmission and crop infection in broiler chickens
Vlková et al. Selection of probiotic bifidobacteria for lambs
Harvey et al. In vitro inhibition of Salmonella enterica serovars Choleraesuis and Typhimurium, Escherichia coli F-18, and Escherichia coli O157: H7 by a porcine continuous-flow competitive exclusion culture
CA2100864C (en) Method for delivering direct feed microorganisms to poultry in ovo
Hidayat et al. Total of Escherichia coli excreta broiler given Enterococcus sp. as probiotics candidate of poultry
KR20140005573A (en) A feed composition for poultry
US9737576B2 (en) Dairy administered bacterial composition
US8673290B2 (en) Sporulation-deficient B. texasporus cells and methods for efficient and cost-effective inactivation and use thereof
Waters et al. Assessment of the effects of Nurmi-type cultures and a defined probiotic preparation on a Salmonella typhimurium 29E challenge in vivo
Limmaneevichitr Probiotics as Antibiotic Alternatives for Salmonella Control in Poultry Industry
KR100489859B1 (en) Viable lactobacilli and method for the treatment and protection of fowl typhoid
Khoury et al. Inhibitory effect of different probiotic formulations on salmonella heidelberg, avian pathogenic escherichia coli and campylobacter jejuni

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807617

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13810549

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2011807617

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011807617

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11807617

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013001107

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013001107

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130116